Bruker Corp (NASDAQ:BRKR) reported mixed fourth-quarter financial results on Thursday.Bruker reported quarterly earnings of 59 cents per share which missed the analyst consensus estimate of 65 cents per share. The company reported quarterly sales of $977.200 million which beat the analyst consensus estimate of $960.834 million.Bruker said it sees FY2026 adjusted EPS of $2.10-$2.15, versus market estimates of $2.13. The company sees sales of $3.570 billion-$3.600 billion versus estimates of $3.470 billion.Br ...

Bruker Corp (NASDAQ:BRKR) reported mixed fourth-quarter financial results on Thursday.Bruker reported quarterly earnings of 59 cents per share which missed the analyst consensus estimate of 65 cents per share. The company reported quarterly sales of $977.200 million which beat the analyst consensus estimate of $960.834 million.Bruker said it sees FY2026 adjusted EPS of $2.10-$2.15, versus market estimates of $2.13. The company sees sales of $3.570 billion-$3.600 billion versus estimates of $3.470 billion.Br ...

Core Viewpoint - Bruker Corporation is facing challenges in maintaining profit margins despite exceeding revenue estimates, leading to a cautious outlook from analysts [5][6]. Financial Performance - Bruker reported Q4 2025 revenue of $977.2 million, a slight decline of 0.2% year-over-year, but above the Zacks Consensus Estimate of $966.4 million, resulting in a positive surprise of 1.12% [2][6]. - The company's EPS for Q4 2025 was $0.59, which fell short of the consensus estimate of $0.65, representing a negative surprise of 9.23% and a decline from the previous year's EPS of $0.76 [3][6]. Stock Performance - The current stock price of $37.51 reflects an approximate decrease of 11.60% from previous levels, with a market capitalization of about $5.7 billion [4]. - Over the past year, BRKR's stock has fluctuated significantly, reaching a high of $56.22 and a low of $28.53 [4]. Analyst Outlook - Jefferies has lowered the price target for BRKR from $55 to $50, influenced by the recent earnings performance and the decline in EPS, despite the company's ability to exceed revenue estimates [5][6].

Non-GAAP diluted EPS was $0.59, down from $0.76 in the year-ago quarter. On a GAAP basis, diluted EPS was $0.10 versus $0.09. Herman also noted the weighted average diluted share count rose 13% year-over-year to 171.7 million shares, reflecting accounting for the mandatory convertible preferred stock offering completed in September 2025.Non-GAAP operating margin was 15.7%, down 240 basis points year-over-year. CFO Gerald Herman said the margin came in about 100 basis points below the company’s expectations, ...

Bruker (NasdaqGS:BRKR) Q4 2025 Earnings call February 12, 2026 08:30 AM ET Company ParticipantsFrank Laukien - President and CEOGerald Herman - EVP and CFOJoe Kostka - Director of Investor RelationsMichael Ryskin - Managing DirectorTycho Peterson - Managing DirectorConference Call ParticipantsBrandon Couillard - Senior Equity AnalystDan Brennan - Managing Director and Senior Equity Research AnalystDoug Schenkel - Managing Director, Senior Research Analyst, and Head of Life Science & Diagnostic ToolsPuneet S ...

Financial Data and Key Metrics Changes - In Q4 2025, Bruker reported revenues of $977.2 million, approximately flat year-over-year, with a currency tailwind of 4.1% and an organic decline of 5.1% [12][27] - For the full year 2025, reported revenues increased by 2.1% to $3.44 billion, with an organic revenue decline of 3.7% [13][32] - Non-GAAP diluted EPS for Q4 2025 was $0.59, down from $0.76 in Q4 2024, reflecting a 22.4% decrease [30] - Non-GAAP operating margin for Q4 2025 was 15.7%, down 240 basis points year-over-year [29] Business Line Data and Key Metrics Changes - The BioSpin group revenue for 2025 was $879 million, declining in the mid-single digits, with solid growth in Chemspeed lab automation offset by declines in NMR instrumentation [15] - The CALID group had revenue of $1.2 billion with constant exchange rate growth in the high single digits, driven by microbiology and infection diagnostics [17] - Bruker Nano revenues for 2025 were $1.1 billion, declining in the low single digits, with growth in spatial biology offset by declines in academia/government and industrial markets [18] Market Data and Key Metrics Changes - In Q4 2025, Americas revenue declined in the low teens%, while European revenue declined in the high single digits%, and Asia Pacific revenue grew in the high single digits% [28] - The U.S. biopharma and industrial growth looked stronger in the second half of 2025, while U.S. government orders remained weak throughout 2025 [23] Company Strategy and Development Direction - Bruker is focused on expanding its leadership in post-genomic disease research and drug discovery tools, particularly in proteomics and multi-omics [19] - The company aims for significant margin expansion, targeting a 250-300 basis points improvement in operating profit margin for 2026 [11][34] - Bruker plans to leverage its recent acquisitions and product innovations to drive revenue growth in 2026 and beyond [8][24] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism about the recovery in demand, particularly in biopharma and industrial research, while acknowledging lingering uncertainties in the U.S. government market [9][49] - The company expects to return to organic revenue growth in the second quarter of 2026, driven by improved order momentum and easier year-over-year comparisons [37][60] - Management highlighted the importance of cost-saving initiatives to mitigate headwinds from tariffs and currency fluctuations [42][68] Other Important Information - Bruker ended Q4 2025 with cash, cash equivalents, and short-term investments of approximately $300 million [31] - The company received major multi-year orders worth over $500 million for superconducting wire from large MRI manufacturers, expected to contribute to revenue in 2026 [18] Q&A Session Summary Question: Margin focus and cost initiatives - Management discussed the focus on cost initiatives to improve margins, expecting annualized savings to exceed $140 million [40][42] Question: Academic and government customer interactions - Management noted that while U.S. government orders were weak, there is cautious optimism for improvement in the second half of 2026 [48][49] Question: Revenue pacing and underlying assumptions - Management indicated that both easier year-over-year comparisons and improving order momentum would contribute to revenue growth starting in Q2 2026 [58][60] Question: Expectations for end markets - Management expects low single-digit organic growth in biopharma and semi, with microbiology showing stronger growth due to increased placements of diagnostic platforms [65][67]

Bruker (NasdaqGS:BRKR) Q4 2025 Earnings call February 12, 2026 08:30 AM ET Speaker8Good morning, everyone, and welcome to the Bruker Corporation fourth quarter 2025 earnings conference call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star and then one using a touchtone telephone. To withdr ...

Bruker (BRKR) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.65 per share. This compares to earnings of $0.76 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -9.23%. A quarter ago, it was expected that this scientific equipment maker would post earnings of $0.33 per share when it actually produced earnings of $0.45, delivering a surprise of +36.36%.Over the last four quarters, t ...

BRUKER CORPORATION (NASDAQ: BRKR) Q4 2025 Earnings Presentation February 12, 2026 Frank H. Laukien, President & Chief Executive Officer Gerald Herman, Executive Vice President & Chief Financial Officer Joe Kostka, Director, Investor Relations BRUKER CORPORATION Safe Harbor Statement Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the S ...

Exhibit 99.1 Bruker Reports Fourth Quarter and Full Year 2025 Financial Results BILLERICA, Massachusetts – February 12, 2026 – Bruker Corporation (Nasdaq: BRKR) today announced financial results for its fourth quarter and for the full year ended December 31, 2025. Frank H. Laukien, Bruker's President and CEO, commented: "At the conclusion of a difficult year 2025, with headwinds from academic funding, tariffs and currencies, we are pleased that in the fourth quarter we delivered revenues ahead of our expect ...